Skip to main content
Top
Published in: Acta Diabetologica 1/2014

01-02-2014 | Original Article

A simplified indication of metabolic syndrome to recognize subjects with a moderate risk to develop type 2 diabetes mellitus in a large Italian sample

Authors: S. Sacco, M. Comelli, V. Molina, P. L. Montrasio, E. Giani, F. Cavanna

Published in: Acta Diabetologica | Issue 1/2014

Login to get access

Abstract

To propose a simplified tool to recognize subjects with a moderate risk to develop type 2 diabetes mellitus (Type 2 DM): this method would take into account only variables from metabolic syndrome definitions which are cheaply assessable. A total of 3,003 employees without diabetes in Italy who attended one annual health examination between 2009 and 2012 were enrolled in this cross-sectional study. A questionnaire was administered along with the annual health examination to record personal and familiar anamnesis. To identify Type 2 DM-prone individuals, the diabetes predictive model by Stern MP et al. was used. Then a multiple logistic regression model was developed using the predicted probability 20 %+ of developing Type 2 DM as the outcome variable and a panel of easily measurable continuous baseline characteristics as explanatory variables (waist circumference, WC; body mass index, BMI; and systolic blood pressure, SBP). The optimism-adjusted area under the curve of the proposed model receiver-operating characteristic (ROC) is 0.90. The effects of the explanatory variables on the presumed Type 2 DM risk are summarized by the following adjusted odds ratio values: 2.65 for SBP (P < 0.001), 2.01 for WC (P = 0.04) and 4.64 for BMI (P < 0.001). The satisfactory ROC of the proposed model suggests the importance of simple assessments in the prognostic information on Type 2 DM risk. Such ease of use may be particularly relevant in populations facing the transition from traditional to industrial food who do not have a sophisticated health service yet.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kishida K, Funahashi T, Shimomura I (2012) Clinical importance of assessment of type 2 diabetes mellitus with visceral obesity. A Japanese perspective. Curr Diabetes Rev 8(2):84–91PubMedCrossRef Kishida K, Funahashi T, Shimomura I (2012) Clinical importance of assessment of type 2 diabetes mellitus with visceral obesity. A Japanese perspective. Curr Diabetes Rev 8(2):84–91PubMedCrossRef
2.
go back to reference Cameron AJ, Zimmet PZ, Soderberg S, Alberti KG, Sicree R, Tuomilehto J, Chitson P, Shaw JE (2007) The metabolic syndrome as a predictor of incident diabetes mellitus in Mauritius. Diabet Med 24(12):1460–1469PubMedCrossRef Cameron AJ, Zimmet PZ, Soderberg S, Alberti KG, Sicree R, Tuomilehto J, Chitson P, Shaw JE (2007) The metabolic syndrome as a predictor of incident diabetes mellitus in Mauritius. Diabet Med 24(12):1460–1469PubMedCrossRef
3.
go back to reference American Diabetes Association (2011) Standards of medical care in diabetes—2011. Diabetes Care 34(Suppl 1):S11–S61CrossRef American Diabetes Association (2011) Standards of medical care in diabetes—2011. Diabetes Care 34(Suppl 1):S11–S61CrossRef
4.
go back to reference Narayan KM, Echouffo-Tcheugui JB, Mohan V, Ali MK (2012) Analysis & commentary: global prevention and control of type 2 diabetes will require paradigm shifts in policies within and among countries. Health Aff (Millwood) 31(1):84–92CrossRef Narayan KM, Echouffo-Tcheugui JB, Mohan V, Ali MK (2012) Analysis & commentary: global prevention and control of type 2 diabetes will require paradigm shifts in policies within and among countries. Health Aff (Millwood) 31(1):84–92CrossRef
5.
go back to reference Stern MP, Williams K, Haffner SM (2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136(8):575–581PubMedCrossRef Stern MP, Williams K, Haffner SM (2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136(8):575–581PubMedCrossRef
6.
go back to reference Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23(5):469–480PubMedCrossRef Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23(5):469–480PubMedCrossRef
7.
go back to reference Cameron AJ, Zimmet PZ, Shaw JE, Alberti KG (2009) The metabolic syndrome: in need of a global mission statement. Diabet Med 26(3):306–309PubMedCrossRef Cameron AJ, Zimmet PZ, Shaw JE, Alberti KG (2009) The metabolic syndrome: in need of a global mission statement. Diabet Med 26(3):306–309PubMedCrossRef
8.
go back to reference Hadaegh F, Ghasemi A, Padyab M, Tohidi M, Azizi F (2008) The metabolic syndrome and incident diabetes: assessment of alternative definitions of metabolic syndrome in an Iranian population. Diabetes Res Clin Pract 80(2):328–334PubMedCrossRef Hadaegh F, Ghasemi A, Padyab M, Tohidi M, Azizi F (2008) The metabolic syndrome and incident diabetes: assessment of alternative definitions of metabolic syndrome in an Iranian population. Diabetes Res Clin Pract 80(2):328–334PubMedCrossRef
9.
go back to reference Ford ES, Schulze MB, Pischon T, Bergmann MM, Joost HG, Boeing H (2008) Metabolic syndrome and risk of incident diabetes: findings from the European prospective investigation into cancer and nutrition-Potsdam study. Cardiovasc Diabetol 7:35PubMedCentralPubMedCrossRef Ford ES, Schulze MB, Pischon T, Bergmann MM, Joost HG, Boeing H (2008) Metabolic syndrome and risk of incident diabetes: findings from the European prospective investigation into cancer and nutrition-Potsdam study. Cardiovasc Diabetol 7:35PubMedCentralPubMedCrossRef
10.
go back to reference Li C, Ford ES, McGuire LC, Mokdad AH, Little RR, Reaven GM (2006) Trends in hyperinsulinemia among nondiabetic adults in the US. Diabetes Care 29(11):2396–2402PubMedCrossRef Li C, Ford ES, McGuire LC, Mokdad AH, Little RR, Reaven GM (2006) Trends in hyperinsulinemia among nondiabetic adults in the US. Diabetes Care 29(11):2396–2402PubMedCrossRef
11.
go back to reference Harrell FE Jr (2001) Resampling, Validating, Describing and Simplifying the model. In Harrell FE Jr. Regression Modeling Strategies (with applications to linear models, logistic regression, and survival analysis). New York: Springer-Verlag 5: 94 Harrell FE Jr (2001) Resampling, Validating, Describing and Simplifying the model. In Harrell FE Jr. Regression Modeling Strategies (with applications to linear models, logistic regression, and survival analysis). New York: Springer-Verlag 5: 94
12.
go back to reference R Core Team (2012) R: A language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing. ISBN 3-900051-07-0. http://www.R-project.org/ Last accessed: 16 January 2013 R Core Team (2012) R: A language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing. ISBN 3-900051-07-0. http://​www.​R-project.​org/​ Last accessed: 16 January 2013
16.
go back to reference Ford ES, Li C, Sattar N (2008) Metabolic syndrome and incident diabetes. Diabetes Care 31:1898–1904PubMedCrossRef Ford ES, Li C, Sattar N (2008) Metabolic syndrome and incident diabetes. Diabetes Care 31:1898–1904PubMedCrossRef
Metadata
Title
A simplified indication of metabolic syndrome to recognize subjects with a moderate risk to develop type 2 diabetes mellitus in a large Italian sample
Authors
S. Sacco
M. Comelli
V. Molina
P. L. Montrasio
E. Giani
F. Cavanna
Publication date
01-02-2014
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 1/2014
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-013-0463-0

Other articles of this Issue 1/2014

Acta Diabetologica 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine